Appendix 4D

Half Year Report, 31 December 2020

COMPANY ANNOUNCEMENT

CLINUVEL REPORTS TENTH CONSECUTIVE

HALF YEAR NET PROFIT

KEY HIGHLIGHTS, HALF YEAR ENDED 31 DECEMBER 2020

CLINUVEL today announced its tenth consecutive half year net profit, released in its Half Yearly Report for the six months ended 31 December 2020. The Company achieved revenues for the period of $15.743 million and posted a half year net profit before tax of $5.811 million.

"CLINUVEL's long-term strategy and focus has been reaffirmed by today's results," CLINUVEL's Chief Financial Officer, Mr Darren Keamy said. "Despite ongoing global economic uncertainty, our team has expanded distribution of our lead drug SCENESSE® in both the USA and Europe through our efficient business model and by exercising financial restraint and control.

"The Company is in a sound financial position to continue to grow and fund its expansion. We are investing in our R&D and clinical programs and progressing our evolution into a diversified pharmaceutical company," Mr Keamy said.

COMMERCIAL AND CLINICAL PROGRESS AND GROWTH

About CLINUVEL PHARMACEUTICALS LIMITED

Media Enquiries

Head of Investor Relations

Investor Enquiries

Forward-Looking Statements

Attachments

  • Original document
  • Permalink

Disclaimer

Clinuvel Pharmaceuticals Limited published this content on 24 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 February 2021 23:53:07 UTC.